

Special Issue

Novel Challenges and Advances in Pediatric Hematology and Hematologic Malignancies

Message from the Guest Editor

Recent advancements have significantly improved diagnostics and therapies in pediatric hematology and hematologic malignancies. Immunotherapies, hematopoietic stem cell transplantation in nonmalignant and malignant hematological disorders, the introduction of long half-life coagulation products for patients with hemophilia, and many others have significantly changed the picture of pediatric hematology. However, there is a continuous need for further development in many fields of patient care to improve the prognosis and quality of life for children with hematologic disorders and malignancies. The Special Issue aims to highlight the latest advances in the clinical, genetic, and therapeutic aspects of children with hematologic disorders or malignancies to provide better information to further improve diagnosis and treatment.


Guest Editor

Dr. Katarzyna Pawińska-Wąsikowska

Department of Pediatric Oncology and Hematology, University Children's Hospital, Jagiellonian University Medical College, 31-008 Krakow, Poland

Deadline for manuscript submissions

closed (25 February 2026)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/212780

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).